Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
July 28, 2022
Earnings Call Speaker Segments
Peter Dannenbaum
executiveGood morning, and welcome to Merck's conference call for the second quarter of 2022. Joining us today are Rob Davis, our President and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Lee, President of Merck Research Labs. Before we begin, there are a few points I want to highlight. You'll notice certain items in our GAAP results, including acquisition-related charges, restructuring costs, and some other items. Please be aware that these have been excluded from our non-GAAP results, and a reconciliation is provided in our press release. I'd also like to remind everyone that some of what we say today may count as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect the current beliefs of Merck's management and carry significant risks and uncertainties. Should our underlying assumptions turn out to be inaccurate or uncertainties occur, actual results could differ materially from what those forward-looking statements indicate. Our SEC filings, including Item 1A and the 2021 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck assumes no obligation to imply update any forward-looking statements. A slide presentation will accompany our speakers' remarks on today's call. The presentation today earnings release as well as our SEC filings are all posted to the Investor Relations section of Merck's website. With that, I'd like to turn the call over to Rob.
Robert Davis
executiveThanks, Peter. Morning, everyone, and I'm glad you could join today's call. It's a point of pride for me that the business continues to perform exceptionally well. Our strategic priorities still serve as our steady compass — pursuing long-term growth and creating value for patients and shareholders. We're capitalizing on the opportunities currently before us, while also making the investments required to carry our success forward well into the future. I'm happy to report that during the second quarter we delivered strong growth across both revenue and earnings, and we also achieved further meaningful clinical progress within our pipeline. Starting with our results: this quarter we again achieved outstanding performance, driven by robust expansion of key products such as KEYTRUDA, GARDASIL and BRIDION. Revenue from LAGEVRIO contributed to our results, and that product is assisting in the fight against COVID-19. We have confidence in underlying demand for our innovative portfolio, since we keep witnessing momentum in our business, and we are pleased that this is reflected in our updated guidance. Now to the research organization: we keep moving our pipeline forward, most notably throughout our pneumococcal vaccine suite. VAXNEUVANCE obtained an expanded FDA approval for the pediatric indication, offering a significant choice for prevention of invasive pneumococcal disease. We additionally shared findings from clinical trials of V116, our vaccine that was created specifically to tackle remaining cases in adults, and we have launched challenging phase III studies. These achievements strengthen our confidence in the population-specific strategy we use to meet the needs of children and adults. We have also made further moves to grasp the substantial opportunities we observe in the pipeline. During June, we held an investor event at ASCO. We emphasized how deep and broad our oncology program is. At that event, we restated our ambition to be the top oncology company by 2025 and our aim to keep that success going far into the coming decade. Looking back on my initial twelve months as chief executive, I feel quite satisfied with how far we've come in strengthening our standing as a worldwide pharmaceutical leader, and with the early momentum now building throughout the company. The steadfast dedication shown by our team members around the globe is fueling solid performance against the considerable opportunity that lies ahead. Despite a highly demanding worldwide climate, we are showing remarkable durability in every part of our operations. Our plants are hitting market-level output, we are posting unusually robust revenue gains, we are achieving meaningful advances in our pipeline, and we are taking significant actions to broaden our horizons. Our approach is delivering results, and the outlook ahead looks very promising. My confidence from twelve months ago has only grown stronger now that we are set up well to hit both our short- and longer-range objectives, built on our pledge to bring meaningful drugs and vaccines to patients while creating value for everyone with a stake in our company, shareholders included. On that note, Caroline will take it from here.
Caroline Litchfield
executiveThanks, Rob, and good morning. As Rob noted, we are carrying forward the powerful momentum established over the course of this year, delivering yet another quarter of outstanding performance on both the top and bottom lines. Once again, these results show that our personal science—the cornerstone of our strategy—is generating returns. What drives that achievement is the exceptional execution of our dedicated products around the world, which keep creating value for patients, customers and shareholders. Company revenues came in at $14.6 billion, up 28%. LAGEVRIO contributed $1.2 billion in revenue. Even without LAGEVRIO, the business still posted very strong growth of 18%. For the rest of my remarks, I'll speak on an ex-exchange basis. Human Health sustained its robust momentum, delivering 33% growth—or 21% excluding LAGEVRIO—driven by our core pillars. Animal Health also turned in a solid quarter, with sales up 5% on gains across both livestock and companion animal offerings. Now to second-quarter results for our major brands. In oncology, KEYTRUDA climbed 30% to $5.3 billion, powered by enormous global demand and further label expansion, and reflecting the early benefit it is bringing to more patients worldwide. In the U.S., KEYTRUDA keeps showing momentum in metastatic indications and is delivering robust gains from recent launches in earlier-stage settings, including triple-negative breast, renal-cell carcinoma and melanoma. KEYTRUDA has won approval across six indications for earlier-stage cancers. Utilization has been robust, and we are confident it will keep succeeding as more physicians and patients gain experience with it. Uptake has been especially strong in neoadjuvant adjuvant high-mileage triple-net breast cancer, supported by KEYNOTE-522, which offers patients a distinct treatment option in an area with considerable unmet need. In the metastatic setting, KEYTRUDA held its leadership position in non-small lung cancer, capturing 8 out of 10 patients. Beyond the U.S., KEYTRUDA's performance was driven by continued uptake in non-small cell lung cancer along with ongoing momentum in neck cancer and renal cell carcinoma. Early signals also show promising patterns across U.S. indications, including breast cancer and renal carcinoma in major European markets. Lynparza remains the leading PARP inhibitor on the market. Lynparza revenue rose 17%, driven by growing uptake among patients with high-risk early-stage breast cancer after FDA approval by <<inaudible>>; we anticipate potentially extending that leadership by reaching the digital prospect cancer patients based on study. Lenvima revenue climbed 33% on the strength of robust demand following the launch of in advanced renal cell carcinoma and PMOT775 in metastatic endometrial cancer. New patient target tumors remain strong. Finally, WELIREG keeps giving us reason for encouragement, and it is tracking in line with expectations. Once again, the portfolio posted a very strong growth rate, and that was thanks to GARDASIL, which rose 40% to $1.7 billion. Beyond the U.S., GARDASIL's substantial growth came from robust underlying demand—especially in China—along with greater supply. The operational strength in our business would have led to an approximately $0.25 increase in our guidance. We increased our expectations of other expense to approximately $500 million, reflecting higher-than-anticipated pension settlement expense. Taken together, we have narrowed our expected EPS range to $7.25 to $7.35. In the U.S., the drop came primarily from how the CDC has been purchasing, and we’re still seeing an effect from <>. We keep putting money into the activation campaign so parents understand why routine vaccination matters for their kids, especially during the <>. On GARDASIL, we remain confident about its growth path, given its proven ability to help prevent certain HPV-related cancers in both females and males. In our hospital acute care portfolio, sales reached 15%, driven by a bigger share among and growth in surgical procedures. Animal health delivered another strong quarter, with sales rising 5%, and grew 6%, supported by stronger demand in and poultry. Companion animal sales climbed 3% on worldwide demand for line of product. Now I’ll walk you through the remainder of our P&L, and all of it is on a non-GAAP basis. Gross margin was 74.7%, a drop of 1.8 percentage points. That decrease came from the impact of <>, a higher inventory baseline and higher manufacturing costs, partially offset by favorable product mix across the rest of the portfolio and foreign exchange. Operating costs fell 19% to $5.2 billion. That reflects charges largely tied to last year’s $1.7 million acquisition, which shows up in our second quarter 2021 R&D expense. Excluding those charges, operating expenses rose in line with our plan, driven by spending on our key growth drivers and pipeline. Other expense was about $200 million, reflecting a pension settlement effect that was bigger than anticipated. Our tax rate was 13.8%. Altogether, we add $1.87 per share. I’ll now turn to our 2022 non-GAAP guidance. The underlying strength of our business lets us rate and narrow our full-year revenue guidance. We now expect revenue of $57.5 billion to $58.5 billion. That higher revenue outlook implies growth of 18% to 20%, or 13% to 14% excluding LAGEVRIO and the effects of foreign exchange. On currency, the anticipated hit now includes an added headwind of over 1% based on this July rate, bringing the total net impact to roughly 3%. Our gross margin forecast is unchanged at 74% to 74.5%. We’re raising our operating expense estimate to $20.5 billion to $21.5 billion, mainly because of the $219 million upfront payment tied to the collaboration with Orion Corporation that we announced recently. As is standard practice, our finance figures don’t factor in significant potential development transactions. We lifted our projection for other expense to roughly $100 million because pension settlement costs came in higher than we expected, and our assumption for the full-year tax rate remains in the 13.5% to 14.5% range. Our share count assumption was 2.54 billion. In total, we’ve steered our expected EPS range to between $725 and $7.35. Operationally, our business would have shown about a 20% lift in guidance. That operational strength would have led to an approximately $0.25 increase in our guidance. We increased our expectations of other expense to approximately $500 million, reflecting higher-than-anticipated pension settlement expense. Taken together, we have narrowed our expected EPS range to $7.25 to $7.35. That strength is being offset by the upfront cost of entering Orion, by pension settlement expense, and by an added foreign exchange headwind of more than 1% due in <>. Broadly, this guidance demonstrates our confidence that our business's strong underlying momentum will carry on through the second half of the year. The operational strength in our business would have led to an approximately $0.25 increase in our guidance. We increased our expectations of other expense to approximately $500 million, reflecting higher-than-anticipated pension settlement expense. Taken together, we have narrowed our expected EPS range to $7.25 to $7.35. As you work through your models, there are a few things to bear in mind. To begin with, the pandemic weighed on growth in the first half, and we anticipate that those benefits will reset on a year-over-year basis across the remainder of the year. Beyond that, we actively handled foreign exchange effects via our revenue saving program. Should we encounter further negative foreign exchange impact, we will see additional benefits from our hedging within other revenues, exactly as happened this quarter. Other revenue likewise encompasses supply to Organon and to Johnson & Johnson for its COVID-19 vaccine, plus what we observe in connection with our out licensing arrangements. Broadly speaking, other revenue for the second half should exceed what we saw in the first half of 2022. On the product side, for <<inaudible>>, we continue to forecast a drag on U.S. sales tied to the move toward the new adults pneumococcal vaccine. Within Animal Health, industry growth is settling into a more normal rate as we deal with unfavorable tailwinds in ending brought on by the pandemic, along with foreign exchange pressures. Even so, our wide innovative portfolio leaves us strongly placed to sustain market growth through 2022 and afterward. Finally, our outlook for the full year remains $5 billion to $5.5 billion in sales, with the second half weighted toward the fourth quarter. Adaptation priorities have not changed. We will keep shedding light on the investments we are making in our pipeline and our business, so that the value of the numerous near- and long-term opportunities in <<inaudible>> can be realized. We are still seeking out attractive strategic business development to supplement our internal pipeline. Our recent collaboration with Orion is one more illustration of how we carry out this strategy. We stay dedicated to our dividend, which we anticipate will rise over the course of time. Lastly, when we have surplus cash, we will give it back to shareholders through share repurchases. In closing, as we reach the end of the second half of the year, our confidence in the business remains very strong, fueled by worldwide demand for our innovative medicines and vaccines. The strong way we carry out our work will let us continue bringing value to patients and shareholders far into the future. With that said, I'd like to hand the call over to Dean now.
Dean Li
executiveThank you, Caroline. I'm glad to share where we stand following our first quarter call. Our pipeline strategy remains in active execution. We're pushing forward the most recent signals to develop medicines and vaccines that deliver clear patient benefit. In my remarks today, I'll focus on recent advances in our vaccine pipeline and give an update on our oncology program along with LAGEVRIO. As Rob mentioned, we've achieved substantial progress throughout our pneumococcal portfolio. This builds on the adult indication approval we obtained 12 months ago. Last month, the FDA granted approval for VAXNEUVANCE, our 15 valent pneumococcal conjugate vaccine — a significant new choice for helping shield pediatric populations from invasive pneumococcal disease. VAXNEUVANCE is the first pneumococcal conjugate vaccine cleared for pediatric populations in close to 10 years. For 12 shared serotypes, VAXNEUVANCE delivers immunogenicity comparable to the currently available 13 valent pneumococcal conjugate vaccine, with improved immunogenicity for serotype 3 and broader coverage of serotypes 22F and 33F. Serotypes 3, 22F and 33F are key invasive disease serotypes known to cause over a quarter of all invasive pneumococcal disease in children. After the FDA approval, the CDC's Advisory Committee on Immunization Practices voted unanimously to recommend VAXNEUVANCE as an option for children under 19 years of age. In addition, the ACID voted unanimously to include VAXNEUVANCE in the vaccines for children program. We are awaiting publication of the final CEC recommendation in the morbidity and mortality weekly report. In June as well, during the International Symposium on pneumococi and pneumococcal diseases held in Toronto, we shared favorable findings from our Phase I/II trial assessing V116—our 21 delink pneumococcal conjugate vaccine candidate—in adults who had not previously received pneumococcal vaccination. V116 has been designed to substantially broaden coverage compared with pneumococcal vaccines currently on the market, targeting serotypes that accounted for 85% of all invasive pneumococcal disease cases among U.S. adults aged 65 and older as of 2019. One clear indicator of how much momentum we have: we just dosed the initial participant in STRIDE 3, a study of V116 in adults with no prior vaccination — the first of four Phase III studies now underway. Our strategy for assembling a pneumococcal vaccine portfolio has been deliberate and customized, aimed at advancing protection by going after the strains that create the biggest danger for particular groups. I'm eager to bring you more news about our pneumococcal work covering VAXNEUVANCE, V116 and V117, our investigational candidate aimed specifically at pediatric illness. Now on to oncology. We continue to build on momentum in earlier-stage cancers; we announced that the FDA has accepted our application for KEYTRUDA in the adjuvant treatment of patients with non-small cell lung cancer following surgical reduction, based on results from the ongoing KEYNOTE-091 trial. The FDA has set a prescription drug user date of January 29, 2023. However, additional data may be provided during the review process that may delay the state. During June's American Society for Clinical Oncology Meeting, we shared broader analyses and delivered findings on additional endpoints across important patient subgroups: 4, KEYNOTE-716 for adjuvant therapy in Stage IIb and IC melanoma; KEYNOTE-522 in neoadjuvant high-risk early-stage triple-negative breast cancer; and KEYNOTE-564 in adjuvant RCC. Our regulatory approach is making headway outside the U.S. as well. Several developments stand out: the European Commission gave KEYTRUDA 4 approvals — one drawing on KEYNOTE-716 for adjuvant therapy in patients aged 12 and up with completely resected Stage IIb or 2C melanoma; another from KEYNOTE-522 covering high-risk early-stage triple-negative breast cancer; KEYNOTE-164 and KEYNOTE-158 for MSI high and/or mismatched tumors spanning 5 distinct cancer types; and KEYNOTE-826 for specific persistent, recurrent or metastatic cervical cancers. In addition, we received a positive EU CHMP opinion for adjuvant LYNPARZA in patients with serotypes of high-risk early-stage breast cancer, backed by the Phase II OLYMPIA trial. To wrap up, we view the favorable results from KEYNOTE-869, also known as EV-103, in first-line urothelial cancer—a partnership with SGI—as encouraging. I’d now like to shift focus to our ongoing prostate cancer efforts. This illness impacts millions of men, and advanced stages are associated with poor 5-year survival rates; through our continued work, we keep deepening our understanding of prostate cancer and remain committed to enhancing patient outcomes. Business development and licensing stay essential to how we build and maintain a robust, varied pipeline. Earlier this month, we announced a worldwide development and commercialization agreement with Orion for ODM-208, an investigational oral steroid synthesis inhibitor currently in Phase II development for metastatic castrate-resistant prostate cancer. ODM-208 is directed at cytochrome P450 1181 — an innovative strategy that works alongside our wide-ranging prostate cancer initiative. That initiative covers KEYTRUDA paired with chemotherapy under KEYNOTE-091, KEYTRUDA plus antiandrogen treatment in KEYNOTE-641 and KEYNOTE-991, and LYNPARZA combined with anti-androgen therapy in the PROPEL trial. Moving on to COVID-19 and LAGEVRIO: the pandemic is still with us, and SARS-CoV-2 continues to change. Strong new data indicate that antibody therapies face a resistance threat from Omicron variants, particularly B4 and B5. The spread rates and greater hospitalization seen with these variants underscore why we need several effective antiviral options, above all for those most at risk. Among high-risk patients, the evidence keeps demonstrating that early therapeutic action led to better outcomes. It's important to note that many high-risk patients—older adults among them—are probably also taking other medicines for chronic conditions. Because LAGEVRIO has a low likelihood of drug-drug interactions, there's no need to change existing dosing schedules or to monitor liver and kidney function while patients are on treatment, and that can help get the right patients treated promptly. Data recently reported from Denmark, Hong Kong and Poland have backed up LAGEVRIO's usefulness in real-world settings. As more data become available, we intend to share them. To close, the progress our pipeline has delivered to date makes me proud, and I look forward to providing further updates on our scientific priorities in the future. With that, I'll turn the call back to Peter.
Peter Dannenbaum
executiveThanks, Dean. Alan, we can move on to questions now. Please put the queue together.
Analyst
analystMaybe this is a two-part question. I'm just wondering whether there's a route to extend the IP on KEYTRUDA, whether through a subcu formulation or perhaps other kinds of formulation patents? And then, from a technical standpoint, is there anything that would prevent a co-formulation of KEYTRUDA with an antibody drug conjugate?
Dean Li
executiveI guess I'll take this one; this is Dean. On the question of alternative ways to deliver the drug, I believe you're right that, especially in earlier-stage cancer, patients and providers alike will want options beyond IV administration, which requires a trip to an infusion center; in that context, subcutaneous pembrolizumab may prove highly valuable in meeting that demand. And if you look at the innovation behind subcutaneous KEYTRUDA in light of the historical record, my sense is that the present situation is novel, useful, and nonobvious. So I think there's a way to approach how one should think about that innovation. Turning to co-formulations. Broadly speaking, co-formulations tend to perform nicely when, say, we pair PD-1 with CTLA-4, TIGIT, or LAG-3 in an IO-IO combination. When it comes to chemo-based approaches or antibody drug conjugates, I'd be somewhat reluctant to go that route. Frequently those are dosed by weight, so combining any IO agent with a chemotherapy or an antibody drug conjugate in a co-formulation, I think, could prove difficult to take into the clinic.
Evan Seigerman
analystGiven all the widespread media coverage about a possible agreement involving Senators management and Schumer, could you share your perspective on how Medicare might be structured to negotiate directly with manufacturers regarding drug reimbursement, and what effect that could have on R&D down the road?
Robert Davis
executiveYes. Evan, appreciate the question. It's Rob here. As you mentioned, reports emerged just yesterday about a possible deal with the Senator, and it contains pieces of what had been included in the build back better plan concerning drug pricing. So when we examine that, I believe it's crucial to recognize, above all, that we hold substantial worry about one particularly significant aspect of the provision — namely the reality that what we perceive as price setting is labeled negotiation. Yet in practice, it amounts to price setting for drugs once a certain period has elapsed. And we firmly believe that will seriously chill future innovation, particularly when you consider a field such as oncology, where drug development carries on well beyond the initial approval. Take KEYTRUDA: at launch in 2014, and across 2014 to 2022, we received approvals for something like 30-plus indications. We anticipate having considerably more than twice that number between 2022 and 2028. And our worry is that once the threat of discounts — mandatory discounts — emerges, companies could begin to second-guess that innovation, since you'll have to ask yourself whether the return will materialize. So we foresee a stronger chilling effect from that, and it's something we'll keep working on — both at our company and across the industry — to ensure our concerns are communicated. And the one other point I might add is that, when you consider how we're thinking about this for our business going forward, it's important to recognize that while this will clearly have an impact, crucially, in planning for the future of the business, we have consistently assumed that some form of pricing pressure would arrive, including within the United States. I believe we've said that previously. So when we look at this, and you consider it against the guidance we've provided before regarding expectations for strong growth across our long-range period — that remains, and it incorporates the assumptions around this. So while I think we'll manage it, I do have concerns about what it will do to innovation within the industry.
Andrew Baum
analystI have a couple of questions. First, you've announced a couple of China licensing deals for ATC. I believe one of those is in late-stage development; it's been widely reported, of course, that you're in discussions with Seagen, which has Phase III data from a different ADC molecule that would compete in HER2. Broadly, I'm just curious — Dr. Pastor appears to have shut the door on pursuing U.S. approval using Chinese trial data. But operationally, how quickly does this let you move, given that you have efficacy and safety signals in a Chinese population, in speeding up the transition into Phase III, meaning is there an advantage here that could let you catch up with the market leaders in the respective categories? And my second question is on islatravir — maybe you'd like to update us on your discussions with Gilead and with the FDA regarding restarting trials. Is this drug still viable as a prophylactic, in PREP, as a treatment, both, or neither?
Dean Li
executiveThis is Dean. Thanks so much for those questions. Let me take your first question about the partnership with Kelyn that we announced recently. I should stress this was announced only recently, but we've had a productive — a really productive — collaboration over the past 2 years. And most recently, they've announced progress on 2 programs. One they've declared relates to Trop-2 ADCs, and they're moving it forward in China in connection with breast cancer and non-small cell lung cancer. Regarding what you said about moving those molecules, for example, in the United States, I think the FDA and we are supportive of this. The FDA has been very clear about the importance of running those trials not in a single geography such as China, but having global studies that include the United States. And so our partners' ability to give us a signal in a human population really matters and lets us navigate how to think about it at a global level. So we're hopeful that this partnership will let us accelerate bringing the benefits of this strong ADC to as many patients as possible. On your second question regarding <<inaudible>>. As you've noticed, islatravir is our nRTTI; it's extremely potent, has a resident time and tissue, and a high barrier to resistance. And we had 2 Phase III studies with excellent results. Nevertheless, we also saw reductions in lymphocytes across a number of our programs, most of it asymptomatic, but in a combo trial with MK-8507, there was a clinically meaningful reduction that's still dependent. We've spent the last 6 months understanding that; we understand it far better now; we believe there's a potential path forward to maintain and have that efficacy while also reducing the effects on the blood cells. We're currently in ongoing talks with the FDA, so I don't want to get ahead of myself on that front, and it's clear we also have active discussions underway with our partners. Regarding the question about treatment and PrEP, I just want to make sure everyone understands that we've always believed this class of molecules — NRTTI and islatravir — meaning just 1 compound within this class could be used broadly for both treatment and PrEP, and we're interested in pursuing both of those — moving both of those possibilities forward, but we're in the middle of discussions with the FDA that I think we should give them the data they will need.
Louise Chen
analystSo I'd like to ask about the checkpoint inhibitor strategy. What's your thinking on how the treatment paradigm for checkpoint inhibitors is shifting in the neoadjuvant and adjuvant cancer setting? How do you view adoption and uptake there? And do you believe physicians are already convinced of the opportunity, or does more work remain?
Dean Li
executiveWell, let me respond from a scientific perspective. Perhaps we'll have Carolina or Rob address it from a market perspective. I really think it's important to emphasize, at least in my view, that PD-1s have been remarkable across a broad range of tumor types in the metastatic setting. And we continue to grow into earlier stages. And it isn't a given that a medicine effective in the metastatic patient, who has a very different benefit/risk ratio, will be truly effective in early stage. And it has been impressive. We have 6 approvals, whether in breast, in renal cell carcinoma and melanoma. And we have a positive trial related to lung, and we have many others moving forward. So I think part of it is that uptake has been good, but the most important thing is that scientifically, the data has been very good. And I believe the field will adopt it. I think one critical thing as the field adopts it is that often you're now not necessarily talking about a medical oncologist. So there will be work for us to do, but I think the results speak for themselves. And I would encourage people to look at that data, and I think it's an important advancement in the field. But regarding uptake, Caroline, would you like to take that?
Caroline Litchfield
executiveYes. Thanks, Dean. Louis, we're really excited about the opportunities ahead as we move into earlier stages of cancer. Clearly, if we're able to help patients at that point, the potential for improved outcomes is greater; we've seen compelling data in our early-stage cancers; we're observing very strong results in triple-negative breast cancer, renal cell carcinoma and melanoma. And if I just mention triple-negative breast cancer, we received the KEYNOTE-522 approval here in the United States in July of last year. In the latter half of last year, we saw enormous uptake in the first portion of treatment, the neoadjuvant treatment before patients then undergo their surgery roughly 24 weeks later. At this point, we're observing two things: patients starting KEYTRUDA for neoadjuvent triple-negative breast cancer, and those same individuals coming back for treatment after surgery. That makes us quite hopeful about what we can accomplish in the adjuvant setting and the difference we can make for patients.
Umer Raffat
analystThere are a couple of points I'd like to raise, if that's alright. To begin with, Rob, I'm aware you've mentioned that M&A is quite important when it comes to moving the business further beyond KEYTRUDA; and you could consider M&A essentially either in a non-oncology field such as Acceleron or within oncology. And I suppose that brings me to my first question, which is that in oncology, having KEYTRUDA as this foundational treatment across so many different tumors is a very high-quality problem; and how do you approach that, given the greater FTC focus on examining many deals based on market shares in individual markets, considering KEYTRUDA essentially holds a market share in treating different tumors. And what's your overall view on oncology deals, particularly with KEYTRUDA's part in them? I'm sure you've thought that through extensively when it comes to any capital deployment you might consider. On a separate note, Rob, you also mentioned drug pricing and mandatory discounts. I'm sure you've done an internal exercise trying to quantify how much in discounts. What I'm driving at is that for key franchises like KEYTRUDA, given that U.S. and ex-U.S. prices are fairly comparable, wouldn't there be very little mandatory discount at all? I just want to confirm I'm not mistaken there, even though KEYTRUDA is a top Part B drug.
Robert Davis
executiveYes. I appreciate the questions. Regarding your initial question about M&A and what we're seeing in oncology: I'll begin by noting that we're clearly very proud of how well KEYTRUDA has performed and that it has reached so many patients, as you mentioned, across a wide range of tumor types. Still, I think it's important to recognize that oncology remains a fiercely competitive area, and crucially, it isn't monolithic. You need to examine each tumor individually, and even each modality—whether that's I/O or targeted therapy. There are several distinct strategies and several modalities involved, and this is highly specific to each tumor type. As you're aware, we must create these medications one indication at a time, putting money into the science to advance each one. With that in mind, when we examine the situation and when we've considered it, our view remains that although the landscape has grown more complicated. Clearly, we’ll need to be very careful in how we handle this. Our view is that if the deals we pursue are grounded in science, speed up innovation, and demonstrate that we can broaden patient access—both globally and within the United States—to these medicines, then there remain transactions worth pursuing and a route to move ahead. That is precisely where our attention is directed, and it is why we still see an opportunity to keep growing treatment options for patients and to benefit, frankly, every stakeholder involved, shareholders included. On your second question, I think it really hinges on how you frame it, especially regarding the regulation that's coming. Clearly, when you examine the proposals out there—and if you're asking specifically about the possibility of required price discounts at some stage—obviously, the final wording still has to be settled. But looking at where things stand today, the proposal as drafted would let you operate without any discount for a stretch of time after a drug's approval, during its exclusivity window—currently that's about 7 years before negotiation for slow molecules and 11 years for large molecules. During that window, there would be a discussion and a chance for HSS to select the drug, based on their judgment about which drugs to target. As the language currently reads, they'd choose 10 drugs per year, with HSS deciding which ones; but crucially, the negotiation itself, once completed and the discount is set—and that discount is spelled out in the legislation—would take effect in year 9 for a small molecule and year 9 for a large molecule. Consider KEYTRUDA: the relevant horizon runs to roughly 2028, when exclusivity is lost. Other wording is circulating that could create an exemption when biosimilars are being developed and are on the way, in which case the provision wouldn't apply. The upshot is that near-term consequences aren't clear, and we don't expect any effect from that specific part of the regulation. For our key products, KEYTRUDA and GARDASIL, it would play out over a longer period. And of course, we'll need to watch how the final text emerges, as well as the discounts that are specified and set. At present, the way they've set it up means it isn't a reference price. Beyond that, obviously, there are the Part B reforms they've proposed, and we actually back those, since we think they'll bring down what patients pay out of pocket at the counter—but we continue to oppose the legislation as a whole because we're firmly convinced that zeroing in on mandatory discounts once a certain period has passed dampens innovation; so I'm not certain I got at what you asked, but that's my sense of your point.
Geoffrey Meacham
analystI've just got a few quick questions. Dean, on KEYNOTE-412, the one that recently — it didn't reach significance — I wanted to ask you: did CRT add complexity to the trial in terms of your assumptions? And stepping back, when you look at other indications, does having a CRT backbone create any particular difficulties for other keynote studies? Then on COVID, with infection trends over this year or any new variants emerging, does that alter the strategy for the future investments you'll be making in LAGEVRIO or even other orals?
Dean Li
executiveOkay. I'll handle both, and I'll start with Keynote-412. You're referring to our effort to move into early stage at a neck, and you're referring to -412 — as you pointed out, there was an improvement in event-free survival for patients who got the KEYTRUDA regimen versus placebo plus DRT; however, those results didn't meet statistical significance under our statistical plan. So there's clearly a positive signal, but it did cross the line. As for how to think about CRT or radiation and other indications here — I wouldn't describe it as giving you extra complication; we'll have to see in those other trials, when — not only us but others — look at the combination there. But I'd just stress that it was an improvement in EFS, so I wouldn't call it a complicating issue for us. We simply did need statistical significance. I do want everyone to recognize that this isn't our only foray into a neck early stage; we also have a KEYNOTE-689 in the neoadjuvant and adjuvant treatment as well. So we're cautiously optimistic about breaking into early stage at a neck despite the fact that KEYNOTE-412, which had a positive EFS, didn't lead to statistical significance. As for the pandemic, I need to be a bit careful, because everyone who's predicted what will happen with the pandemic has shared one common thread; they've all been not so right. So we'll have to see what happens with the pandemic. We'll have to see what the emergence of resistance is, but I'd stress that having multiple mechanisms of action is clearly important. I'd just stress that it's quite surprising to me how quickly this virus can mutate around those therapies, for example, focused on this like protein. That actually takes many amino-acid changes to do it. It may only require a handful of amino acid alterations for resistance to emerge against, say, other treatments—though we'll need to determine whether that's the case. I'd also like to stress that, particularly beyond the United States, usage and adoption have been substantial, and that stems largely from this: when you have a patient population you consider highly vulnerable, you can administer this drug, and your main goal is lowering mortality—which this drug affects impressively—and you want speed so you can actually evaluate the patient, who may be taking several medications and have other complicating medical conditions, and feel confident giving this, then if those are the key attributes, we've observed that LAGEVRIO performs quite well, and real-world evidence globally has started to confirm that.
Caroline Litchfield
executiveAnd Jeff, Caroline here. The one additional point I'd make regarding further investments is our conviction that this molecule could have an impact not just against COVID-19, but also on pan coronavirus, RSA, and flu. So because of that, we'll put money into suitable programs to try to demonstrate it.
Mara Goldstein
analystFirst off, I'd like to get some clarity on what was said regarding the KEYTRUDA supplemental PDUFA in neoadjuvant and adjuvant non-small cell lung cancer? And has the company received any request for additional data? Or is a major amendment being planned? Then, secondly, I was hoping for some clarity too on the remark about excess cash being used for share repurchase. And at what threshold should we think about that, given that you're also committed to raising the dividend?
Dean Li
executiveYes. So I'll — Dean here. I'll address the KEYNOTE-091, which is the lung adjuvant study. And just as a reminder to everyone, that trial had dual primary endpoints; and the reason I want to stress that is that dual primary means hitting one of the endpoints gives you a positive trial. That differs from trials that are co-primary, where both must be hit. So this is a positive trial because in disease-free survival, it's positive across all comers regardless of PD-L1. On the dual primary of DFS for those with a TPS greater than 50%, there is a positive trend, but it isn't significant; and OS shows a trend as we move forward. I would imagine, as the data mature, people may want to see those data, and I want to stress that in relation to early-stage lung cancer, we have other trials too, namely KEYNOTE-671, KEYNOTE-867 and KeyLink 012. So I could imagine that as people deliberate on this, they'll be interested in understanding how the data are maturing. These are event-driven and they're part of our FDA discussions, and the PDUFA date, as you said, is January 29, 2023. But we could see a situation. Nothing has been formally asked of us, but we could see a situation where evolving data is requested.
Caroline Litchfield
executiveAnd Mara, regarding what you asked about how we're using excess cash — our company's priorities for allocating capital haven't changed. First and foremost, we keep investing in our business and in the great opportunities ahead of us. Business development remains a strategic priority for us, and we will put money into business development just as we've done previously. Our intention is to keep raising our dividend over time, and after that we'll return any excess cash to shareholders through share buybacks; we don't plan to sit on multiple capacity on our balance sheet for stretches of time without putting that cash to work in this way. So I hope that answers the question about our use of cash.
Seamus Fernandez
analystMaybe just a single M&A question, then. When it comes to any acquisition plans, or whatever Merck might look at, can you make clear whether those would probably be all cash, or whether equity could be part of the mix and potentially considered in a deal. And then on a separate note, I'd like to hear a little about the vision for V116. In the overall market, where and how do you expect V116 to compete? Are we really viewing it only as a possible opportunity among adults? Or do you also see the '21 balance being a target opportunity with high use in the pediatric patient population as well. And then I'd like to understand the timing for when V116 might actually be competing in the market, and how you expect the overall market to evolve over time?
Robert Davis
executiveYes. Thanks for the question, Seamus. As we've discussed, business development continues to be a priority for us; and importantly, we aim to add wherever we can identify the best science and innovations that strengthen our pipeline and generate long-term growth and value for shareholders. I'd rather not speculate about specific future transactions or the particular mix of cash or equity we'd use, since that really would depend on the facts of the deal at hand. So in that sense, I think we'd need to hold off. The bigger point I want to stress—and we've said this all along—is that we've got the capital and balance-sheet strength to pursue whatever we believe is strategically important and delivers the scientific innovation I referred to, which lets us keep adding to what's already in our internal pipeline. So we have the capacity and flexibility to structure things in whatever way we see as best for optimizing the business; how you split that among cash, debt and equity really depends on the specific deal.
Dean Li
executiveYeah, regarding the questions you raised about V116, I want to restate and underline our thinking on strategy — namely that the stereotypes causing the most difficulty differ greatly across age groups and populations. So the entire emphasis of V116, the entire emphasis of V116, is on identifying the serotypes that matter specifically for adults and going after them. That is exactly what V116 is, and that is the reason we had the first of 4 current Phase III trials that have to run its course. From my standpoint, scientifically, there is no view that this is a vaccine I would push into the pediatric population, because the epidemiology as of right now would indicate that would not be the right place to put this vaccines. We want to put the vaccines where the serotypes match what is happening to that patient population.
Robert Davis
executiveYes, let me just add something there. When we think about the commercial future, we see a genuine opportunity with this tailored approach—actions we believe will be highly effective against the serotypes responsible for disease in infants and children through our pediatric strategy. Then there's a separate approach with V116 targeting the adult market; we'll pursue 85% of the residual disease, recognizing that once you've addressed it in children, the serotypes driving disease in adults are clearly a different set. We're concentrating on both as bespoke therapies designed to match most closely what those populations need. I believe this will be highly effective and will let us be very competitive—in fact, covering more disease-causing serotypes than competitor products cover today, whether you look at what they have in the pediatric or the adult market; so this is something we're quite excited about. And in fact, we view V116 as truly the fruition of a strategy. So we're excited about it, and we're going to move with speed, because I do think this is an area where we can definitely be highly competitive and successful.
Carter Gould
analystDean, a quick one from me — I'd like to return to the subcutaneous version of pembro. Is that Phase III trial in non-small cell still expected to report early next year? And how should we think about the clinical measures in that study — I believe the primary end points relate to some of the biomarker endpoints? And on its own, should that study be enough to warrant a filing? Or should we be thinking about it another way?
Dean Li
executiveYes. I want to stress that the trial remains on track, and our intention is that it should support filings. I should also stress that we have more than just 1 subcutaneous program, with different images and different subcutaneous, since we believe there may be a different patient population that will matter for different formulations — the group formulations. I should also stress that just as we have Q3 weeks and weeks Q3 weeks and Q6 weeks intravenously, I think it's also important that we open up that possibility in the subcutaneous range as well.
Executive
executiveThanks so much, Carter. Rob, would you like to offer any final remarks?
Robert Davis
executiveYes. Well, I simply want to thank everybody for being with us today, and perhaps I'll wrap up by restating how much I value the enormous efforts put in by the Merck team — and truly, we keep delivering exceptionally well even in a challenging environment as we push our science forward and make sure our vital medicines and vaccines get to patients across the globe who depend on us; so I'm grateful for that, and I can tell you, my confidence in our underwriting momentum stays very strong, and I look forward to bringing you further updates on our progress going forward. With that, have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.